|
19 December 2006
Capital Raising to Progress PI-88 Towards Phase 3
13 December 2006
Dec 2006 HCC Data for Investors, Presentation
13 December 2006
Open Briefing, Progen's CEO on Phase II Preliminary Results
13 December 2006
Progen Reports Positive Results for Phase II Liver Cancer Trial
13 December 2006
Appendix - Detailed Clinical Trial Information
30 November 2006
Results of the 2006 AGM
30 November 2006
AGM 2006 Chairman's Address
30 November 2006
AGM 2006 CEO's Address
29 November 2006
FDA Provides Manufacturing Clearance for Phase III Trial of Anti-Cancer Drug
30 October 2006
AGM Notice
4 October 2006
Progen changes its NASDAQ ticker symbol to PGLA
31 August 2006
Progen's Financial Year ends with a positive outlook for 2007
31 August 2006
Preliminary Final Report 30 June 2006
16 May 2006
Clarification of the date for the Investor Teleconference
16 May 2006
Progen Prepares for Accelerated Clinical Development of PI-88 Following FDA Meeting
7 April 2006
CEO Presentation at Australian Biotechnology Expo (New York)
3 April 2006
AACR Poster
27 March 2006
Shanghai Poster
27 March 2006
Progen meets with FDA to progress PI-88 clinical development
14 March 2006
Progen Half Yearly Financial Results
14 March 2006
Appendix 4D - Half Year report 31 December 05
20 February 2006
New CEO to lead Progen through next stages of Cancer Drug Development
|